Tweet
Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating in a research report issued on Wednesday, Marketbeat Ratings reports. They currently have a $244.00 price objective on the biopharmaceutical company's stock. Royal Bank of Canada's target price suggests a potential upside of 136.41% from the stock's current price. The analysts noted that the move was a valuation call.
Other equities analysts have also issued reports about the company. Wedbush reaffirmed a "buy" rating on shares of Intercept Pharmaceuticals in a report on Friday, May 18th. Zacks Investment Research lowered Intercept Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, August 7th. Cantor Fitzgerald reaffirmed a "hold" rating and set a $58.00 target price on shares of Intercept Pharmaceuticals in a report on Tuesday, May 8th. Oppenheimer set a $100.00 target price on Intercept Pharmaceuticals and gave the company a "hold" rating in a report on Thursday, August 2nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 2nd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $123.81. Get Intercept Pharmaceuticals alerts:
NASDAQ:ICPT opened at $103.21 on Wednesday. The company has a market cap of $3.36 billion, a PE ratio of -7.17 and a beta of -1.68. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $121.92. The company has a debt-to-equity ratio of 2.48, a current ratio of 6.51 and a quick ratio of 6.51. Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.83) by $0.25. The company had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.26 million. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The business's revenue was up 41.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.46) earnings per share. equities research analysts anticipate that Intercept Pharmaceuticals will post -10.86 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new position in shares of Intercept Pharmaceuticals during the second quarter worth approximately $852,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Intercept Pharmaceuticals by 436.7% during the second quarter. Metropolitan Life Insurance Co. NY now owns 7,170 shares of the biopharmaceutical company's stock worth $602,000 after buying an additional 5,834 shares during the period. Macquarie Group Ltd. boosted its position in shares of Intercept Pharmaceuticals by 42.0% during the second quarter. Macquarie Group Ltd. now owns 13,742 shares of the biopharmaceutical company's stock worth $1,153,000 after buying an additional 4,062 shares during the period. Natixis acquired a new position in shares of Intercept Pharmaceuticals during the second quarter worth approximately $729,000. Finally, Voya Investment Management LLC boosted its position in shares of Intercept Pharmaceuticals by 30.5% during the second quarter. Voya Investment Management LLC now owns 8,461 shares of the biopharmaceutical company's stock worth $710,000 after buying an additional 1,978 shares during the period. Institutional investors and hedge funds own 66.63% of the company's stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter . Comment on this Pos